173 related articles for article (PubMed ID: 37147783)
1. Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple-Negative Breast Cancer.
Cao Y; Ge X; Zhu X; Han Y; Wang P; Akakuru OU; Wu A; Li J
Adv Sci (Weinh); 2023 Jul; 10(21):e2300545. PubMed ID: 37147783
[TBL] [Abstract][Full Text] [Related]
2. A self-cascaded unimolecular prodrug for pH-responsive chemotherapy and tumor-detained photodynamic-immunotherapy of triple-negative breast cancer.
Yao D; Wang Y; Bian K; Zhang B; Wang D
Biomaterials; 2023 Jan; 292():121920. PubMed ID: 36442436
[TBL] [Abstract][Full Text] [Related]
3. Prodrug nanoparticles potentiate tumor chemo-immunometabolic therapy by disturbing oxidative stress.
Zhao H; Li Y; Shi H; Niu M; Li D; Zhang Z; Feng Q; Zhang Y; Wang L
J Control Release; 2022 Dec; 352():909-919. PubMed ID: 36370878
[TBL] [Abstract][Full Text] [Related]
4. The novel platinum(IV) prodrug with self-assembly property and structure-transformable character against triple-negative breast cancer.
Yang C; Tu K; Gao H; Zhang L; Sun Y; Yang T; Kong L; Ouyang D; Zhang Z
Biomaterials; 2020 Feb; 232():119751. PubMed ID: 31918218
[TBL] [Abstract][Full Text] [Related]
5. Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment.
Zhu X; Li C; Lu Y; Liu Y; Wan D; Zhu D; Pan J; Ma G
Acta Biomater; 2021 Jan; 119():337-348. PubMed ID: 33166712
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional Polymeric Prodrug with Simultaneous Conjugating Camptothecin and Doxorubicin for pH/Reduction Dual-Responsive Drug Delivery.
Dong S; Sun Y; Liu J; Li L; He J; Zhang M; Ni P
ACS Appl Mater Interfaces; 2019 Mar; 11(9):8740-8748. PubMed ID: 30693750
[TBL] [Abstract][Full Text] [Related]
8. ROS-responsive Galactosylated-nanoparticles with Doxorubicin Entrapment for Triple Negative Breast Cancer Therapy.
Zhou J; Li K; Zang X; Xie Y; Song J; Chen X
Int J Nanomedicine; 2023; 18():1381-1397. PubMed ID: 36987427
[TBL] [Abstract][Full Text] [Related]
9. Acid-labile polysaccharide prodrug via lapatinib-sensitizing effect substantially prevented metastasis and postoperative recurrence of triple-negative breast cancer.
Sui J; Zhao M; Yang Y; Guo Z; Ma M; Xu Z; Liang J; Sun Y; Fan Y; Zhang X
Nanoscale; 2020 Jul; 12(25):13567-13581. PubMed ID: 32555923
[TBL] [Abstract][Full Text] [Related]
10. A pH-Sensitive Prodrug Nanocarrier Based on Diosgenin for Doxorubicin Delivery to Efficiently Inhibit Tumor Metastasis.
Wei Z; Wang H; Xin G; Zeng Z; Li S; Ming Y; Zhang X; Xing Z; Li L; Li Y; Zhang B; Zhang J; Niu H; Huang W
Int J Nanomedicine; 2020; 15():6545-6560. PubMed ID: 32943867
[TBL] [Abstract][Full Text] [Related]
11. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
[TBL] [Abstract][Full Text] [Related]
12. pH/ROS dual-responsive supramolecular polypeptide prodrug nanomedicine based on host-guest recognition for cancer therapy.
Ding Y; Wang C; Ma Y; Zhu L; Lu B; Wang Y; Wang J; Chen T; Dong CM; Yao Y
Acta Biomater; 2022 Apr; 143():381-391. PubMed ID: 35272024
[TBL] [Abstract][Full Text] [Related]
13. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy.
Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X
Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753
[TBL] [Abstract][Full Text] [Related]
14. Targeted treatment of triple-negative-breast cancer through pH-triggered tumour associated macrophages using smart theranostic nanoformulations.
Scialla S; Hanafy MS; Wang JL; Genicio N; Costa Da Silva M; Costa M; Oliveira-Pinto S; Baltazar F; Gallo J; Cui Z; Bañobre-López M
Int J Pharm; 2023 Feb; 632():122575. PubMed ID: 36603672
[TBL] [Abstract][Full Text] [Related]
15. Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
He X; Cai K; Zhang Y; Lu Y; Guo Q; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Li C; Sun T; Cheng J; Jiang C
ACS Appl Mater Interfaces; 2018 Nov; 10(46):39455-39467. PubMed ID: 30362704
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy.
Shim N; Jeon SI; Yang S; Park JY; Jo M; Kim J; Choi J; Yun WS; Kim J; Lee Y; Shim MK; Kim Y; Kim K
Biomaterials; 2022 Oct; 289():121806. PubMed ID: 36156411
[TBL] [Abstract][Full Text] [Related]
17. A tumor-specific ROS self-supply enhanced cascade-responsive prodrug activation nanosystem for amplified chemotherapy against multidrug-resistant tumors.
Wang J; Zhang H; Lv J; Zheng Y; Li M; Yang G; Wei X; Li N; Huang H; Li T; Qin X; Li S; Wu C; Zhang W; Liu Y; Yang H
Acta Biomater; 2023 Jul; 164():522-537. PubMed ID: 37072069
[TBL] [Abstract][Full Text] [Related]
18. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier.
Sun JJ; Chen YC; Huang YX; Zhao WC; Liu YH; Venkataramanan R; Lu BF; Li S
Acta Pharmacol Sin; 2017 Jun; 38(6):823-834. PubMed ID: 28504251
[TBL] [Abstract][Full Text] [Related]
19. Photo-responsive prodrug nanoparticles for efficient cytoplasmic delivery and synergistic photodynamic-chemotherapy of metastatic triple-negative breast cancer.
Jiao J; Lu H; Wang S
Acta Biomater; 2021 May; 126():421-432. PubMed ID: 33774201
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the anti-cervical cancer effect of a prodrug ：CBZ-AAN-DOX with hypoxic cell culture and tumor-bearing zebrafish models.
Chen HC; Rui W; You SY; Liu XW; Huang J; Chen HY
Exp Cell Res; 2020 Jun; 391(1):111980. PubMed ID: 32229193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
